Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs).
Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
We are building a pipeline of ADCs centred on:
• PermaLink® – proprietary conjugation chemistry for improved ADC stability
• Novel ultra-potent toxins for improved tumour killing
• Novel antibodies targeted towards well-selected antigens associated
primarily with solid tumours
We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours such as lung, ovarian, cervix, pancreatic and colorectal.
Our first wave ADC programmes include antibodies with proven premise in ADC formats and novel DNA damaging payloads.
We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes.
We have developed a series of high-value ADC assets, which are available for collaborative research and license.
Location: United Kingdom, England, Newcastle upon Tyne
Employees: 11-50
Total raised: $47M
Founded date: 2007
Investors 2
Date | Name | Website |
20.06.2023 | Premier Pa... | premierpar... |
- | Mirae Asse... | vc.miraeas... |
Funding Rounds 1
Date | Series | Amount | Investors |
08.06.2021 | - | $47M | - |
Mentions in press and media 10
Date | Title | Description | Source |
22.06.2021 | LegoChem Biosciences and Iksuda Therapeutics expand licence ... | LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-dr... | cambridgen... |
22.06.2021 | IP : Iksuda Therapeutics Ltd - LegoChem Biosciences and Iksu... | Expanded agreement grants Iksuda access to Legochem Biosciences' next generation ADC platform for up... | marketscre... |
08.06.2021 | Iksuda Therapeutics Raises $47M in Funding | Iksuda Therapeutics, a Newcastle UK-based company focused on developing antibody drug conjugates (AD... | finsmes.co... |
08.06.2021 | IP GROUP PLC IP : Iksuda Therapeutics Ltd - Closes $47 mill... | • Funding to accelerate clinical progression of Iksuda's pipeline of new generation of antibody drug... | marketscre... |
08.06.2021 | IP : Iksuda Therapeutics Ltd - Closes $47 million financing ... | • Funding to accelerate clinical progression of Iksuda's pipeline of new generation of antibody drug... | marketscre... |
07.06.2021 | The SoftBank bets that aren’t doing so great | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
07.06.2021 | Iksuda Therapeutics closes $47 million financing round | Newcastle, UK, 07 June 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug... | cambridgen... |
07.06.2021 | Iksuda Therapeutics closes $47 million financing round | Iksuda Therapeutics closes $47 million financing round 07-06-2021 Newcastle, UK, 07 June 2021: Iks... | cambridgen... |
07.06.2021 | Iksuda Therapeutics : Closes $47 Million Financing Round | Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) w... | marketscre... |
07.06.2021 | Iksuda raises $47M to take CD19 antibody-drug conjugate into... | Iksuda Therapeutics has raised $47 million to take a CD19-targeted antibody-drug conjugate (ADC) int... | fiercebiot... |